Detected ·
Vaderis Therapeutics
$152M—
Vaderis Therapeutics closed a private $152M Series B financing to advance engasertib, a Phase 3 candidate for hereditary hemorrhagic telangiectasia (HHT).
- Website
- vaderis.com
- Amount
- $152 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-09-24 04:22:39 UTC
- Signal ID
- ce659708-faec-4327-ae79-071c926c5b50
As the API returns it
{
"id": "ce659708-faec-4327-ae79-071c926c5b50",
"created_at": "2026-09-24T04:22:39.883839Z",
"company_name": "Vaderis Therapeutics",
"company_website_url": "vaderis.com",
"company_linkedin_url": "https://www.linkedin.com/company/vaderis-therapeutics-ag",
"event_type": "funding",
"funding_amount": 152000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Vaderis Therapeutics closed a private $152M Series B financing to advance engasertib, a Phase 3 candidate for hereditary hemorrhagic telangiectasia (HHT).*"
}